《大行》里昂升H&H國際控股(01112.HK)目標價至13.5元
里昂研究報告指,H&H國際控股(01112.HK)發盈警料中期純利跌幅介乎45%至65%,經調整淨利潤增長1%至15%,銷售額增長中單位數。該行見到其嬰兒配方奶粉業務(IMF)有良好勢頭,因有效吸納新客戶,而成人營養與護理產品(ANC)及寵物營養與護理產品(PNC)業務亦有加速增長的潛力。
該行將H&H國際控股2025年淨利潤預測下調17%,以反映債務置換引致的一次性成本,同時將2026至27年的淨利潤預測上調3%至5%,以反映成人營養與護理產品業務的穩健表現及嬰兒配方奶粉業務的良好勢頭。將目標價由11.5元升至13.5元,維持「跑贏大市」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.